MXCT maxcyte.com: Forward P/S Multiple

Graphic logo of MaxCyte, Inc (MXCT)

The development of MaxCyte, Inc. (MXCT) depends on partner investments in cell engineering. The projected P/S ratio helps track such risks, with the 3.60 mark indicating the level of market expectations. MaxCyte, Inc. (MXCT) generates revenue through the sale of Expertita systems and recurring payments for cartridges. Long-term agreements with pharma behemoths ensure a stable cash flow and revenue predictability.

maxcyte.com - MXCT Market Cap to Expected Sales Ratio (period 07/04/2022 - 11/13/2026)

Metric breakdowns and analytics for MaxCyte Inc (MXCT)

- current price and projected stock value:
Stock Price MaxCyte|MXCT - Average Forecast Price
- company stock capitalization data:
Market Capitalization MaxCyte Inc|MXCT - Business Value
- issuer book value statistics:
Book Value per Share MaxCyte|MXCT - Book Valuation of Business|Market Capitalization to Book Value Ratio maxcyte.com|MXCT - Cumulative Company Assets
- company total debt and liquidity indicators:
Total Debt to Capital MaxCyte, Inc.|MXCT - Long-Term Debt to Capital|Short-Term Debt to Equity MaxCyte, Inc.|MXCT - Company Debts|Debt to Book Value MaxCyte Inc|MXCT - Company Long-Term Loans and Borrowings|Company Short-Term Debts MaxCyte|Quick Liquidity maxcyte.com
- financial results and valuation multiples details:
MXCT - Annual Net Income|Future Profit MaxCyte, Inc.|MXCT - P/E Multiple|Forward P/E Multiple MaxCyte, Inc|MXCT - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MaxCyte Inc|MXCT - Profit before deduction of interest, taxes, depreciation and amortization|Earnings per share for the last twelve months MaxCyte|MXCT - Net earnings per share for the last 12 months|Quarterly EPS earnings growth maxcyte.com|MXCT - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year MaxCyte, Inc.
- sales volume and revenue indicators:
MXCT - Company Sales Volume|Company Future Sales Volume MaxCyte|MXCT - Market Cap to Sales Volume|Price-to-Projected Revenue Ratio MaxCyte Inc
Summary company analytics:MaxCyte (MXCT)
Product sample of MaxCyte, Inc.

To assess the fundamental quality of MaxCyte, Inc. (MXCT), investors must correlate market capitalization with expected revenue adjusted for currency fluctuations. By analyzing the forward P/S ratio, one can filter out market noise and discern the real value of future flows, which is supported by growing demand for electroporation systems within the global genome editing sector and an expanding client base.

Key competitors

Forward P/S Multiple ABT (Abbott)|Thermo Fisher Scientific Inc. (TMO) - Market Cap to Future Revenue Ratio|GE Healthcare Corp - Forward P/S Multiple|MTD (Mettler Toledo Inc) - Market Cap to Projected Revenue|WAT: Forward P/S Multiple|TECH - Market Cap to Expected Sales Ratio|BRKR (Bruker) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Azenta Inc (AZTA)|Forward P/S Multiple VREX|Forward P/S Multiple Semler (SMLR)|Price-to-Projected Revenue Ratio Butterfly Network, Inc. BFLY|mesalabs.com - Price-to-Projected Revenue Ratio|QSI: Forward Price-to-Revenue Multiple|Forward Price to Sales NNOX (Nano-X Imaging)|QTRX: Forward P/S Multiple|Market Cap to Future Revenue Ratio 908 Devices Corporation (MASS)|Price-to-Projected Revenue Ratio CapsoVision, Inc.|RPID - Projected Price to Revenue|Forward Price-to-Revenue Multiple SEER (Seer)|Forward P/S Multiple Hyperfine Inc (HYPR)|Forward P/S Multiple FONR (FONAR Corp)|Market Cap to Expected Sales Ratio Daxor Corp (DXR)|MDAI - Price-to-Projected Revenue Ratio|Future Price to Revenue VIVS|Aclarion, Inc. (ACON) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Akoya Biosciences, Inc.|THMO (ThermoGenesis Holdings Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Talis Biomedical Corp TLIS|Price-to-Projected Revenue Ratio T2 Biosystems, Inc. (TTOO)